Wester and Kessler review evidence supporting the promise of polyvalent αvβ3-integrin antagonists, such as peptide multimers and peptide-polymer conjugates, as ligands for use in radiotherapeutic targeting of integrins involved in angiogenesis.
Boswell and Brechbiel outline the rationale for the utility of a new class of trifunctional somatostatin analogs (described elsewhere in this issue) that are transported into both targeted tumor cells and into the nuclei, where Auger electrons are most lethal.
Jacobs and colleagues compare the diagnostic effectiveness of 18F-fluoro-l-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in primary central nervous system tumors.
Lopresti and colleagues describe simplified methods for analysis of retention of the amyloid-binding Pittsburgh Compound in PET imaging in patients with Alzheimer’s disease and in healthy individuals.
Yamauchi and colleagues use 11C-flumazenil PET to measure benzodiazepine receptors to determine whether selective neuronal damage is associated with border-zone infarction in internal carotid artery occlusive disease.
Costes and colleagues describe the binding potential of 18F-MPPF, a novel serotonin 5-HT1A antagonist PET tracer with promise in serotoninergic system imaging, and discuss the importance of a robust normative database for additional research.
Heston and Sigg quantify the relative contributions of end-diastolic and end-systolic volumes to an optimized stress-induced volume ratio in patents undergoing gated SPECT imaging for myocardial ischemia.
Pellegrino and colleagues assess the relationship between brachial artery flow–mediated dilation and coronary flow reserve as estimated by sestamibi imaging in patients with peripheral artery disease.
Elhendy and colleagues investigate whether stress 99mTc-tetrofosmin myocardial perfusion imaging can independently provide information for predicting mortality in patients with stable angina pectoris.
Khorsand and colleagues evaluate myocardial electrocardiography-gated 13N-ammonia PET in the simultaneous assessment of myocardial perfusion, left ventricular geometry, and contractile function.
Bleeker-Rovers and colleagues assess the value of 18F-FDG PET imaging in detecting metastatic infectious foci in patients with bacteremia or fungemia at high risk of metastatic infection.
Lejeune and colleagues use a decision analysis model to compare the cost effectiveness within the French health care system of CT with and without PET in the diagnosis and staging of patients with metachronous liver metastases of colorectal cancer.
Wieder and colleagues evaluate chemotherapy-induced changes in tumor glucose use and tumor size in patients with adenocarcinoma of the esophagogastric junction undergoing 18F-FDG PET and CT imaging before, during, and after neoadjuvant chemotherapy.
Boersma and colleagues review the clinical relevance, limitations, and potential applications of visualizing apoptosis with the programmed cell–detecting protein annexin A5.
Hartung and colleagues explore the effects of dietary modification and statin therapy (measures known to favorably influence outcomes in coronary disease) on apoptosis in experimental atherosclerotic lesions.
Verwijnen and colleagues compare the renal uptake effects of oral and intravenous administration of d-lysine in rats injected with 111In- DTPA-octreotide, in an effort to surmount current limitations in tumor therapy with radiolabeled somatostatin analogs.
Bäck and colleagues investigate the relative biological effectiveness of the α-emitter 211At and that of 60Co γ-irradiation in a mouse radioimmunotherapy model of intraperitoneal ovarian cancer.
Buursma and colleagues evaluate the feasibility of monitoring gene therapy with the human norepinephrine transporter as a reporter gene in combination with the reporter probe 11C-m-hydroxyephedrine in PET imaging.
Essman and colleagues determine the distribution of 153Sm-EDTMP, a focus of interest in the treatment of primary osteosarcoma, within the tibias of juvenile rabbits and estimate the radiation-absorbed doses delivered to the physeal cartilage.
Brambilla and colleagues report the results of performance measurements for the lutetium oxyorthosilicate–based whole-body PET/CT scanner Biograph 16 HI-REZ using the National Electrical Manufacturers Association NU 2-2001 standard.
Boecker and colleagues quantify the binding kinetics of the novel PET tracer 18F-FDPN for opiodergic system imaging and assess the effects of scanning duration in an effort to determine an optimal protocol.
Ginj and colleagues report on the design, synthesis, and preclinical assessment of new trifunctional conjugates of somatostatin that target the nucleus to provide a better carrier for Auger electron–emitting radionuclides and ensure longer retention in tumor cells.
Kersemans and colleagues describe and evaluate the tumor-detecting characteristics and kinetics of 123/125I-2-iodo-d-phenylalanine, a radiolabeled amino acid analog with promise in diagnostic imaging.
Brogsitter and colleagues investigate whether intraarterial application of 131I-MIBG has the potential to enhance tumor uptake in a population of patients with primary or metastasized neuroendocrine tumors.
ON THE COVER
The newly developed 18F-FLT PET is compared with the routinely used 11C-MET PET and contrast-enhanced MRI in these images of a 26-y-old woman with a WHO grade I astrocytoma. The findings illustrate the ability of 18F-FLT PET to determine DNA metabolism and amino acid uptake, as well as the integrity of the blood–brain barrier, in patients with gliomas and clarify the role of 18F-FLT in the diagnosis of primary central nervous system tumors.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.